Identification of tRNA-Derived Fragments Expression Profile in Breast Cancer Tissues

Wang, Xiaoming; Yang, Yining; Tan, Xiaojie; Mao, Xuelian; Da, Wang; Yao, Yufeng; Jiang, Pan; Mo, Dongping; Wang, Ting; Yuan, Feng

doi:10.2174/1389202920666190326145459

Cited by 33 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tsRNA-26576 upregulation induced migration while suppressing the cellular apoptosis, and served as a potential target therapy and also a predictive marker [43]. In another research, down-regulation of tRF-32-Q99P9P9NH57SJ and tRF-17-79MP9PP were indicated as well as up regulation of tRF-32-XSXMSL73VL4YK [44]. Using high-throughput sequencing, circulating tDR-7816 was predicted as an oncogene effect on xenobiotic metabolic processes in early non-TNBC breast cancer.…”

Section: Breast Cancermentioning

confidence: 97%

Dynamic Signature of tRNA-Derived Small RNAs in Cancer Pathogenesis as a Promising Valuable Approach

Vafaei

Fattahi

Sahlolbei

et al. 2020

Crit Rev Eukaryot Gene Expr

View full text Add to dashboard Cite

Background: Non-coding RNAs are a cluster of RNAs that do not encode functional proteins, and involve infrastructural and regulatory types, which transfer RNAs (tRNAs) belong to former and small RNAs (sRNA) to the latter one. Recently, tRNA-derived small RNAs (tDRs) were discovered among small non-coding RNA, as the newly discovered regulatory small RNA. It plays a role in pathological and physiological processes, which is frequently dysregulated in gene expression regulation. tsRNAs can be bounded to argonaute proteins and piwi proteins such as miRNAs and piRNAs sequentially. In addition, it can interact with DNA and histone methylation machinery Results: In initial searching, 2744 unique articles were identified by bio electronically search of following databases: PubMed, Embase, Web of Science, Scopus, and google scholar up to 25 February 2020. Finally, after Full-text assessment 48 related article to gene expression profiling tsRNA in cancer were achieved. Conclusions: In this systematic review, we summarized the most recent findings related to the expression of tsRNAs in 17 cancer types. We suggested that tsRNA in cancer field attracted the researchers' focus and effectively facilitated diagnostic and therapy approaches. There is little consensus over tRF production mechanism, and dicer-dependent cleavage of mature tRNAs has been suggested [11]. Dysregulation of tsRNAs could interfere in the gene expression in pre/post transcriptional and protein translation. Furthermore, researchers target the tsRNA via gene repression of mRNAs, reported construct silencing, translation inhibition, cell proliferation modulation, exonuclease mRNAs Xrn2-mediated degradation, Ybx1 protein displacement, and sense-induced trans-silencing [12]. Moreover, they have been engaged in cellular and pathophysiological tools, concerning porphyrin biosynthesis, reverse transcription, cell proliferation, differentiation, viability, cell signalling, control of viral replication, and utterly in disease ranging from metabolic disorders and neuro degenerative disease to various types of cancer [13-19]. At first, in 2009, small RNA sequencing data was recognized as tsRNA in prostate cancer [20]. Then, the scientists analyzed more samples, which were abundant in small RNA [21]. They declared that, this biomarker could be potentially applied in many cancer types as a screening and even be targeted for therapy. Moreover, tsRNA is essential in cell cycle proliferation and propagation as well as playing a significant role in tumorigenesis either oncogenic or tumor-suppressor functions [22]. Besides, induction and dysregulation of a set of hypoxia related tsRNAs and also tsRNA suppressive factors in Notch signaling pathway can help in maintenance and metastasis of cancer stem cell [23, 24]. Unfortunately, the exact pathway of tsRNA in cancer has not been clarified yet and we design the schematic of tRNA-derived small RNAs biogenesis in Fig. 1. In this systematic review, we summarized the frequency and function of tsRNAs in different cancer types. Met...

show abstract

Section: Breast Cancermentioning

confidence: 97%

Dynamic Signature of tRNA-Derived Small RNAs in Cancer Pathogenesis as a Promising Valuable Approach

Vafaei

Fattahi

Sahlolbei

et al. 2020

Crit Rev Eukaryot Gene Expr

View full text Add to dashboard Cite

show abstract

“…They are expressed and dysregulated in various cancers [58] (Table 1). The heterogeneity and stability of tRFs make it suitable biomarkers for cancer diagnosis and prognosis [19]. Acquired treatment resistance is the main dilemma of cancer treatment [59].…”

Section: Classification Of Trfs and Tirnas And Their Roles In Cancersmentioning

confidence: 99%

“…5′-tiRNA Val tiRNA-5 5′-tiRNAVal overexpression significantly suppresses breast tumor cell proliferation, migration and invasion. [18] tRF-32-Q99P9P9NH57SJ tiRNA-5 tumour stage and lymph node metastasis [19] SHOT-RNAAsp-GUC SHOT-RNAHis-GUG SHOT-RNALys-CUU tiRNA SHOT-RNAs enhance cell proliferation. [20] tDR-000620 tRF aggressive phenotype of breast cancer stem cells [21] 5′-tiRNA Asp , 5′-tiRNA His tiRNA-5 elevate in breast cancer [22] tRF tRF Leu − CAG tiRNA-5 Promote cell proliferation and G0/G1 cell cycle progression [27] pancreatic cancer AS-tDR-000064 AS-tDR-000069 AS-tDR-000102 AS-tDR-001391 tiRNA-5 diagnostic and therapeutic biomarkers [28] colorectal cancer tRF/miR-1280 tRNALeu and pre-miRNA suppress colorectal cancer growth and metastasis [29] tiRNA-Tyr-GTA tiRNA-5 Targets of tiRNA-Tyr-GTA are mainly enriched in the PPAR signaling pathway.…”

Section: Mechanisms Of Breast Cancer Resistance Related To Trfs and Tmentioning

confidence: 99%

“… [ 17 ] 5′-tiRNA Val tiRNA-5 5′-tiRNAVal overexpression significantly suppresses breast tumor cell proliferation, migration and invasion. [ 18 ] tRF-32-Q99P9P9NH57SJ tiRNA-5 tumour stage and lymph node metastasis [ 19 ] SHOT-RNAAsp-GUC SHOT-RNAHis-GUG SHOT-RNALys-CUU tiRNA SHOT-RNAs enhance cell proliferation. [ 20 ] tDR-000620 tRF aggressive phenotype of breast cancer stem cells [ 21 ] 5′-tiRNA Asp , 5′-tiRNA His tiRNA-5 elevate in breast cancer [ 22 ] tRF Glu-YTC tRF Asp-GTC tRF Gly-TCC i-tRF suppress cell proliferation and cancer metastasis [ 23 ] tRF Ser-GCT i-tRF Unknown [ 24 ] tRF-2 derived from tRNA Glu , tRNA Asp , tRNA Gly , and tRNA Tyr tRF-2 Bind to YBX1 by displacing 3′-UTR, thus suppressing cancer cell growth and metastasis [ 25 ] ts-46, ts-47 tRF-1 ts-46 and ts-47 are upregulated by PIK3CA and KRAS mutations, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

Zhang

Qian

et al. 2020

Biomark Res

View full text Add to dashboard Cite

The tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) are newly discovered noncoding RNAs in recent years. They are derived from specific cleavage of mature and pre-tRNAs and expressed in various cancers. They enhance cell proliferation and metastasis or inhibit cancer progression. Many studies have investigated their roles in the diagnosis, progression, metastasis, and prognosis of various cancers, but the mechanisms through which they are involved in resistance to cancer treatment are unclear. This review outlines the classification of tRFs and tiRNAs and their mechanisms in cancer drug resistance, thus providing new ideas for cancer treatment.

show abstract

“…tRNA-derived RNA fragments (tRFs) are sncRNAs that are derived from the 5′ or 3′ end of mature or precursor tRNAs [ 12 ]. Recent advances in sequencing technology have facilitated the determination of the expression profiles of tRFs in various cancers, including breast, colon, pancreatic, and prostate cancers [ 13 , 14 , 15 ]. Compared to other studies that have reported the tRF profiles of other carcinomas, studies on prostate cancer have progressed from the determination of tRF expression profiles to the use of tRFs therapeutically or diagnostically [ 12 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

tRNALys-Derived Fragment Alleviates Cisplatin-Induced Apoptosis in Prostate Cancer Cells

et al. 2021

View full text Add to dashboard Cite

Cisplatin is a standard treatment for prostate cancer, which is the third leading cause of cancer-related deaths among men globally. However, patients who have undergone cisplatin can rxperience relapse. tRNA-derived fragments (tRFs) are small non-coding RNAs generated via tRNA cleavage; their physiological activities are linked to the development of human diseases. Specific tRFs, including tRF-315 derived from tRNALys, are highly expressed in prostate cancer patients. However, whether tRF-315 regulates prostate cancer cell proliferation or apoptosis is unclear. Herein, we confirmed that tRF-315 expression was higher in prostate cancer cells (LNCaP, DU145, and PC3) than in normal prostate cells. tRF-315 prevented cisplatin-induced apoptosis and alleviated cisplatin-induced mitochondrial dysfunction in LNCaP and DU145 cells. Moreover, transfection of tRF-315 inhibitor increased the expression of apoptotic pathway-related proteins in LNCaP and DU145 cells. Furthermore, tRF-315 targeted the tumor suppressor gene GADD45A, thus regulating the cell cycle, which was altered by cisplatin in LNCaP and DU145 cells. Thus, tRF-315 protects prostate cancer cells from mitochondrion-dependent apoptosis induced by cisplatin treatment.

show abstract

Identification of tRNA-Derived Fragments Expression Profile in Breast Cancer Tissues

Cited by 33 publications

References 37 publications

Dynamic Signature of tRNA-Derived Small RNAs in Cancer Pathogenesis as a Promising Valuable Approach

Dynamic Signature of tRNA-Derived Small RNAs in Cancer Pathogenesis as a Promising Valuable Approach

Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance

tRNALys-Derived Fragment Alleviates Cisplatin-Induced Apoptosis in Prostate Cancer Cells

Contact Info

Product

Resources

About